Operating
D&A
Gilead Sciences D&A increased by 1686.7% to $1.61B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.6%, from $1.60B to $1.61B. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 8.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Peer comparison
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
Metric ID:
cf_depreciation_and_amortizationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.00M | $441.00M | $445.00M | $445.00M | $445.00M | $445.00M | $445.00M | $546.00M | $598.00M | $598.00M | $597.00M | $596.00M | $98.00M | $94.00M | $1.60B | $599.00M | $93.00M | $90.00M | $1.61B |
| QoQ Change | — | +0.2% | +0.9% | +0.0% | +0.0% | +0.0% | +0.0% | +22.7% | +9.5% | +0.0% | -0.2% | -0.2% | -83.6% | -4.1% | >999% | -62.5% | -84.5% | -3.2% | >999% |
| YoY Change | — | — | — | — | +1.1% | +0.9% | +0.0% | +22.7% | +34.4% | +34.4% | +34.2% | +9.2% | -83.6% | -84.3% | +167.7% | +0.5% | -5.1% | -4.3% | +0.6% |
Range$90.00M – $1.61B
CAGR+33.4%
Avg YoY Growth+8.6%
Median YoY Growth+0.9%
D&A at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's d&a?
- Gilead Sciences (GILD) reported d&a of $1.61B in Q4 2025.
- How has Gilead Sciences's d&a changed year-over-year?
- Gilead Sciences's d&a increased by 0.6% year-over-year, from $1.60B to $1.61B.
- What is the long-term trend for Gilead Sciences's d&a?
- Over 4 years (2021 to 2025), Gilead Sciences's d&a has grown at a 8.6% compound annual growth rate (CAGR), from $1.72B to $2.39B.
- What does d&a mean?
- The accounting process of spreading the cost of physical and intangible assets over time.